Vaginal inserted estradiol pharmaceutical compositions and methods
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
1. A method of treating a female patient with a symptom of vulvovaginal atrophy, the method comprising administering to a female patient in need thereof, an intravaginal softgel insert, the insert comprising:
a. 10 mcg of estradiol, the estradiol being the only active pharmaceutical ingredient in the softgel insert; and
b. a liquid solvent system having a viscosity between about 50 cP and about 1000 cP at 25° C., the solvent system consisting of a 9:1 w/w ratio of (i) one or more C6 to C14 fatty acid mono-, di-, or triesters of glycerol to (ii) a nonionic surfactant consisting of PEG-6 stearate, PEG-32 stearate, and ethylene glycol palmitostearate,
wherein
after a single administration of the softgel insert to the female patient in need thereof, the patient achieves at least one of:
i. a peak plasma concentration (C max ) of 17β-estradiol of about 12 pg/ml to about 18 pg*hr/ml; or
ii. a mean area under the curve (AUC 0-24 ) of 17β-estradiol of about 42 pg*hr/ml to about 63 pg/ml.
2. The method of claim 1 , wherein the female patient in need thereof achieves both:
a. a peak plasma concentration (C max ) of 17β-estradiol of about 12 pg/ml to about 18 pg/ml; and
b. a mean area under the curve (AUC 0-24 ) of 17β-estradiol of about 42 pg*hr/ml to about 63 pg*hr/ml.
3. The method of claim 1 , wherein systemic estradiol exposure following administration of the softgel insert is not significantly different than systemic estradiol exposure resulting from administration of a placebo.
4. A method of treating a female patient with a symptom of vulvovaginal atrophy, the method comprising administering to a female patient in need thereof, an intravaginal softgel insert, the insert comprising:
a. 4 mcg of estradiol, the estradiol being the only active pharmaceutical ingredient in the softgel insert; and
b. a liquid solvent system having a viscosity between about 50 cP and about 1000 cP at 25° C., the solvent system consisting of a 9:1 w/w ratio of (i) one or more C6 to C14 fatty acid mono-, di-, or triesters of glycerol to (ii) a nonionic surfactant consisting of PEG-6 stearate, PEG-32 stearate, and ethylene glycol palmitostearate,
wherein
after a single administration of the softgel insert to the female patient in need thereof, the patient achieves at least one of:
i. a peak plasma concentration (C max ) of 17β-estradiol of about 4 pg/ml to about 8 pg/ml; or
ii. a mean area under the curve (AUC 0-24 ) of 17β-estradiol of about 16 pg*hr/ml to about 26 pg*hr/ml.
5. The method according to claim 4 , wherein the female subject in need thereof achieves both:
a. a peak plasma concentration (C max ) of 17β-estradiol of about 4 pg/ml to about 8 pg*hr/ml; and
b. a mean area under the curve (AUC 0-24 ) of 17β-estradiol of about 16 pg*hr/ml to about 26 pg*hr/ml.
6. The method of claim 4 , wherein systemic estradiol exposure following administration of the softgel insert is not significantly different than systemic estradiol exposure resulting from administration of a placebo.